Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 5/2015

01-10-2015 | Original Article

Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists

Authors: Hidde J. Braam, Djamila Boerma, Marinus J. Wiezer, Bert van Ramshorst

Published in: International Journal of Clinical Oncology | Issue 5/2015

Login to get access

Abstract

Background

Controversy still exists regarding the position of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis of colorectal carcinoma. The goal of the current study was to evaluate the opinions about this treatment among Dutch oncologic surgeons and medical oncologists.

Methods

An online survey was sent to all known Dutch oncologic surgeons (n = 459) and medical oncologists (n = 363) representing the respective departments of 84 hospitals. A comparison was made between surgeons and oncologists.

Results

185 eligible responses were received from 71 hospitals, resulting in a response rate of 23 % for individuals and a response rate of 85 % for hospitals. Overall, 65 % of respondents regarded CRS+HIPEC as effective with sufficient evidence, 29 % responded that CRS+HIPEC is probably effective without sufficient evidence, and 7 % of respondents regards HIPEC as probably ineffective. Medical oncologists were less convinced of the effectiveness of CRS+HIPEC than surgeons (P = 0.006). Of all the respondents, 68 % indicated that they regard CRS+HIPEC as a standard treatment for patients with peritoneal dissemination of colorectal carcinoma (77 % of surgeons vs 54 % of oncologists, P = 0.001). Additionally, 68 % of respondents regard CRS+HIPEC as potentially curative (77 % of surgeons vs 54 % of oncologists, P = 0.001).

Conclusions

Approximately 30 % of physicians who treat colorectal carcinoma do not regard CRS+HIPEC as standard care. Surgeons appear to be significantly more in favor of this treatment than medical oncologists. This study shows that efforts should be made to improve knowledge and increase acceptance of CRS and HIPEC in colorectal cancer treatment among medical oncologists and surgeons.
Appendix
Available only for authorised users
Literature
1.
2.
Cao C, Yan TD, Black D et al (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16(8):2152–2165CrossRefPubMed
3.
Hompes D, D’Hoore A, Wolthuis A et al (2014) The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol 109(6):527–532CrossRefPubMed
4.
Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743CrossRefPubMed
5.
Spiegle G, Schmocker S, Huang H et al (2013) Physicians’ awareness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis. Can J Surg 56(4):237–242PubMedCentralCrossRefPubMed
6.
Thomassen I, Bernards N, van Gestel YR et al (2014) Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin. Acta Oncol 53(3):429–432CrossRefPubMed
7.
Klaver YL, Lemmens VE, Creemers GJ et al (2011) Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 22(10):2250–2256CrossRefPubMed
8.
9.
Van Cutsem E, Nordlinger B, Cervantes A et al (2010) Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 21(Suppl 5):v93–v97CrossRefPubMed
10.
(2011) Diagnosis and management of colorectal cancer. Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh
11.
Poston GJ, Tait D, O’Connell S et al (2011) Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 9(343):d6751CrossRef
12.
Benson AB, Venook AP, Bekaii-Saab T et al (2014) Colon cancer, version 3. J Natl Compr Canc Netw. 12(7):1028–1059PubMed
13.
Australian Cancer Network Colorectal Cancer Guidelines Revision Committee (2005) Guidelines for the prevention, early detection and management of colorectal cancer. The Cancer Council Australia and Australian Cancer Network, Sydney
14.
Pox C, Aretz S, Bischoff SC et al (2013) S3-guideline colorectal cancer version 1.0. Z Gastroenterol 51(8):753–854CrossRefPubMed
15.
(2014) National working group on gastrointestinal cancers. Colorectal carcinoma, national guideline. version 3.0
16.
Grossmann I, de Bock GH, van de Velde CJ et al (2007) Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Colorectal Dis 9(9):787–792CrossRefPubMed
17.
Wevers KP, Hoekstra-Weebers JE, Speijers MJ et al (2014) Cutaneous melanoma: medical specialists’ opinions on follow-up and sentinel lymph node biopsy. Eur J Surg Oncol 40(10):1276–1283CrossRefPubMed
Metadata
Title
Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists
Authors
Hidde J. Braam
Djamila Boerma
Marinus J. Wiezer
Bert van Ramshorst
Publication date
01-10-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 5/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0816-5

Other articles of this Issue 5/2015

International Journal of Clinical Oncology 5/2015 Go to the issue

Original Article

Treatment outcomes of external-beam radiotherapy for squamous cell carcinoma of the base of the tongue

Original Article

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial

Original Article

Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer

Original Article

Oncological benefit of primary tumor resection with high tie lymph node dissection in unresectable colorectal cancer with synchronous peritoneal metastasis: a propensity score analysis of data from a multi-institute database

Original Article

Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer

Introduction to Review Articles

ISRT: a new radiation therapy for malignant lymphomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits